Scancell Holdings plc

Equities

SCLP

GB00B63D3314

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 06:36:43 2024-05-23 EDT			5-day change	1st Jan Change
9.716 ^GBX	-3.80%		-3.80%	-7.47%

03-26	Scancell doses first patient in melanoma-focused trials	AN
03-22	Seneca Growth Capital announces tepid 2023 results	AN

Scancell Holdings Names Jean-Michel Cossery Nonexecutive Chairman

February 01, 2023 at 04:31 am

By Anthony O. Goriainoff

Scancell Holdings PLC said Wednesday that Jean-Michel Cossery has been appointed nonexecutive chairman of the board with immediate effect, and that Chairman John Chiplin will step down following this appointment.

The London-listed biopharmaceutical company said Mr. Cossery has more than 25 years of experience in the pharmaceutical and biotechnology industries, having been vice president for North America Oncology at Eli Lilly & Co. He also served as vice president and chief marketing officer at GE HealthCare Technologies Inc. global headquarters.

Shares at 0912 GMT were up 0.50 pence, or 2.6%, at 19.75 pence.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

02-01-23 0431ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GE HEALTHCARE TECHNOLOGIES INC.	80.62 USD	-1.61%	-1.57%	36.8B
	SCANCELL HOLDINGS PLC	9.716 GBX	-3.80%	-3.80%	105M

Latest news about Scancell Holdings plc

Scancell doses first patient in melanoma-focused trials	03-26	AN
Seneca Growth Capital announces tepid 2023 results	03-22	AN
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board	03-14	CI
Alliance Pharma appoints chair; FireAngel sales down	02-05	AN
Scancell's Chief Development Officer to Step Down	02-05	MT
Scancell Holdings plc Directorate and Executive Changes Changes	02-05	CI
Scancell interim loss narrows amid finance gain on derivative	01-30	AN
Scancell Holdings plc Reports Earnings Results for the Half Year Ended October 31, 2023	01-30	CI
Scancell approved by MHRA to add new cohort to Scope trial	01-17	AN
Scancell Holdings plc Announces Update on SCOPE Trial	01-17	CI
Scancell Raises GBP1.2 Million Via Open Offer	12-19	MT
Scancell raises GBP12 million in total from fundraise	12-19	AN
Scancell Raises GBP11 Million via Share Issue	12-01	MT
Scancell raises GBP10.7 million in upsized share sale	12-01	AN
EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen	11-30	AN
Scancell’s Skin Cancer Vaccine Trial Advances to Second Stage; Shares Up	11-28	MT
Scancell trial progresses; OptiBiotix inks new deal	11-28	AN
Scancell shares up as presents "trailblazing" trial data	11-10	AN
EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss	23-10-31	AN
Earnings Flash (SCLP.L) SCANCELL HOLDINGS Reports FY23 Revenue GBP5.3M	23-10-31	MT
Scancell Holdings plc Reports Earnings Results for the Full Year Ended April 30, 2023	23-10-31	CI
Scancell says needs more time to publish annual results	23-10-20	AN
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free	23-09-28	CI
Oxford Technology 2 VCT asset value hurt by AIM share falls	23-09-22	AN
Scancell celebrates "positive" clinical trial data for cancer vaccine	23-09-19	AN

Chart Scancell Holdings plc

Duration

Period

More charts

Company Profile

Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - Sachs Oncology Innovation Forum

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.101 GBP

Average target price

0.2467 GBP

Spread / Average Target

+144.23%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SCANCELL HOLDINGS PLC	-7.47%	105M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+45.43%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research